TICKERNERD
Menu
SBFMSBFMHealthcare · Drug Manufacturers - Specialty & Generic

SBFM Stock Forecast: Sunshine Biopharma, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$0.70
+75.88% on the day

The 1 Wall Street analysts covering Sunshine Biopharma, Inc. hold a median 12-month price target of $56 — +7900.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 7 Oct 2026 — in the upper half.

Market cap
$1.7M
Ticker Nerd rank
61 / 100
Median analyst target
$56
Analysts covering
1
Revenue$9.3M−1.6% y/y
Operating income−$1.6M
Net income−$1.6M
Free cash flow−$923K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.4%
1M
−38.6%
YTD
−94.3%
1Y
−95.8%
From 52W high
−96.8%
From 52W low
+75.9%
$0
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SBFM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sunshine Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Revisions
87
Quality
80
Growth
70
Accruals
63
Issuance
32
Momentum
23
Volatility
10
Value
4

Size (98): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SBFM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SBFM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26SBFMHigh $56Median $56Low $56

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $56Median $56High $56

The green dot is the last close — the median target sits +7900.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Oct 2025Aegis CapitalReiteratesBuy$7.00
5 Dec 2024Aegis CapitalReiteratesBuy—
7 Aug 2023Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SBFM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SBFM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Sunshine Biopharma, Inc. returned −95.8% against +17.4% for the S&P 500, dividends included.

SBFM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26SBFMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SBFM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Sunshine Biopharma, Inc. (SBFM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
0.0×

Cheaper than 98% of US stocks

Price / book
0.0×

Cheaper than 91% of US stocks

EV / EBITDA
2.4×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
−1.6%

Higher than 25% of US stocks

Earnings growth (YoY)
−1.6%

Higher than 34% of US stocks

Gross margin
26.2%

Higher than 29% of US stocks

Operating margin
−17.4%

Higher than 22% of US stocks

Net margin
−16.5%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−21.9%

Higher than 31% of US stocks

Return on assets
−9.9%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sunshine Biopharma, Inc. (SBFM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sunshine Biopharma, Inc. has a market value of $1.7M and an enterprise value of −$11.8M.

  • Revenue in the twelve months to 30 June 2026: $35.3M. The latest quarter shrank 1.6% year on year.

  • Net income over the same four quarters: −$5.8M, a −16.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$5.5M.

  • Shares outstanding: 2.4M.

  • Trailing P/E: 0.2×; forward P/E: 0.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Sunshine Biopharma, Inc. employs 50 people — $707K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

SBFM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SBFMSunshine Biopharma, Inc.$1.7M
61
IMCCIM Cannabis Corp.$3.1M
20
PRFXPRF Technologies Ltd.$2.7M
4
SXTCChina Sxt Pharmaceuticals, Inc.$3.7M
9
YCBDcbdMD, Inc.$4.6M
34
SNOASonoma Pharmaceuticals, Inc.$5.8M
35
GELSGelteq Ltd.$6.0M
11

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sunshine Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SBFM news & analysis

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

Accesswire · 8 Oct 2026neutral

Sunshine Biopharma announced pricing of a public offering expected to generate approximately $6.0 million in gross proceeds before fees and expenses. The offering comprises 10,909,083 common or pre-funded units, each with two Series D warrants exercisable at an initial price of $0.66 per share.

Why it matters — The offering's terms and expected proceeds are relevant to SBFM watchers tracking the company's financing and potential share issuance.

Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research · 24 Sept 2026positive

Sunshine Biopharma, Inc. (SBFM) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade suggests the stock could move higher as analysts reassess its outlook.

Why it matters — An upgrade to a Buy rating signals increased analyst confidence in SBFM's earnings potential, which SBFM watchers would view as a constructive development for the stock.

Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio

Accesswire · 24 Sept 2026positive

Sunshine Biopharma announced the launch of generic Ondansetron 4 mg and 8 mg tablets (the generic equivalent of Zofran) in Canada, for nausea and vomiting associated with chemotherapy, radiation therapy and surgery. The rollout is supported by Nora Pharma's Canadian distribution network, expanding Sunshine Biopharma's generic prescription drug portfolio in oncology supportive care.

Why it matters — The Canadian launch adds a new generic oncology supportive-care product to SBFM's portfolio and leverages an established distribution network, potentially broadening its commercial reach in a growing global ondansetron market.

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Accesswire · 16 Sept 2026positive

Sunshine Biopharma announced it has advanced its lead Coronavirus drug candidate into IND-enabling studies. The candidate reportedly shows nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variant activity, dose-dependent suppression of pulmonary viral replication in vivo, and strong oral bioavailability with preferential lung enrichment across multiple species.

Why it matters — This milestone moves the company's antiviral program toward potential regulatory submission, which could be a significant development for SBFM watchers tracking the company's pipeline.

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

Accesswire · 31 Aug 2026positive

Health Canada approved Sunshine Biopharma's Atenolol tablets in 25mg, 50mg, and 100mg doses for the Canadian market. Atenolol is the generic equivalent of the brand-name drug Tenormin, used for treating and managing cardiovascular conditions.

Why it matters — This regulatory approval expands Sunshine Biopharma's approved product portfolio in the Canadian market, adding a cardiovascular treatment option to its generic and specialty medications.

FAQ

Frequently asked questions about SBFM stock

What is the SBFM stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Sunshine Biopharma, Inc. have a median 12-month price target of $56, with estimates ranging from $56 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SBFM stock a buy right now?

Of the 1 analysts covering Sunshine Biopharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sunshine Biopharma, Inc. 61 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SBFM?

As at 7 Oct 2026, Sunshine Biopharma, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will SBFM stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +7900.0% from the last close, and Ticker Nerd's factor model ranks Sunshine Biopharma, Inc. 61 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SBFM stock forecast for 2030?

No analyst covering Sunshine Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SBFM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $56 to $56 over the next 12 months.

How has SBFM stock performed over the past year?

Sunshine Biopharma, Inc. returned -95.8% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sunshine Biopharma, Inc. do?

Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets.

What is the latest news on SBFM?

The most recent item we track (Accesswire, 8 Oct 2026): "Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering". Sunshine Biopharma announced pricing of a public offering expected to generate approximately $6.0 million in gross proceeds before fees and expenses. The offering comprises 10,909,083 common or pre-funded units, each with two Series D warrants exercisable at an initial price of $0.66 per share.

Company

About Sunshine Biopharma, Inc.

Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets. The company’s current business spans prescription generic pharmaceuticals and nonprescription over-the-counter products through its operating subsidiaries, alongside a proprietary drug-development pipeline targeting areas with significant unmet medical need. Its portfolio includes generic prescription medicines available in Canada, science-based nutritional supplements, and research programs centered on small-molecule, mRNA, and protease-inhibitor candidates. Sunshine Biopharma Inc. serves as a diversified life-sciences platform that combines marketed healthcare products with ongoing therapeutic development, giving it a role in both established pharmaceutical distribution and early-stage drug innovation. Headquartered in Fort Lauderdale, Florida, the company operates primarily in the United States and Canada.

CEO Dr. Steve N. Slilaty Ph.D. · 50 employees · United States · https://sunshinebiopharma.com